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The interaction between fosfomycin (FOS) and bovine serum albumin (BSA) has been investigated ef-
fectively by multi-spectroscopic techniques under physiological pH 7.4. FOS quenched the intrinsic
ﬂuorescence of BSA via static quenching. The number of binding sites n and observed binding constant KA
were measured by the ﬂuorescence quenching method. The thermodynamic parameters ΔG0, ΔH0 and
ΔS0 were calculated at different temperatures according to the van’t Hoff equation. The site of binding of
FOS in the protein was proposed to be Sudlow’s site I based on displacement experiments using site
markers viz. warfarin, ibuprofen and digitoxin. The distance r between the donor (BSA) and acceptor
(FOS) molecules was obtained according to the Förster theory. The effect of FOS on the conformation of
BSA was analyzed using synchronous ﬂuorescence spectra (SFS), circular dichroism (CD) and 3D ﬂuor-
escence spectra. A molecular modeling study further conﬁrmed the binding mode obtained by the ex-
perimental studies.
& 2015 Xi'an Jiaotong University. Production and hosting by Elsevier B.V. All rights reserved. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Serum albumins (52%–60% of the total amount of plasma pro-
teins) are the major soluble protein constituents of the circulatory
system, and they have many physiological functions, such as
combination with many endogenous and exogenous compounds.
They also play an important role in storage and transport of energy
[1]. BSA solution is stable and homogeneous; the 3D structure of
BSA is believed to be similar to that of human serum albumin
(HSA). BSA has two tryptophan residues (Trp 134 and Trp 212)
located in sub-domains IA and IIA, respectively [2].
Fosfomycin (FOS) is a naturally occurring antibiotic that was
described originally under the name fosfonomycin in 1969 [3]. FOS
is a clinically useful antibiotic for the treatment of limb-threa-
tening diabetic foot infections and lower urinary tract infections
[4]. It is reasonably soluble in water [5] and the drug substance is
stable under normal storage conditions (2–3 years). Chemical
structures of BSA and FOS are shown in Supplementary Fig. S1.
The literature survey revealed that attempts have not been
made so far to investigate the binding mechanism of FOS with BSA
by spectroscopic techniques like synchronous ﬂuorescence spectraon and hosting by Elsevier B.V. All
University.
: þ91 836 2747884.
atadar).(SFS), circular dichroism (CD) and 3D spectra. We further in-
vestigated the effect of ﬂuorescence resonance energy transfer
(FRET) and the conformational change of BSA. In the present study
of the binding mechanism between FOS and BSA regarding the
binding parameters, the thermodynamic functions and the effect
of FOS on the protein conformation were investigated in detail.2. Experimental
2.1. Materials and methods
Fosfomycin disodium salt was obtained from HIMEDIA (India).
Protease-free and essentially globulin-free BSA (Fraction V) was
purchased from Sigma Chemical Co. (St. Louis, USA). The stock
solution of BSA (65,000) and FOS was prepared in 0.1 M phosphate
buffer of pH 7.4 containing 0.15 M NaCl. All other materials were of
analytical reagent grade and millipore water (resistivity of milli-
pore water is 20 MΩ) was used throughout the experiment.
2.2. Instruments
Fluorescence measurements were recorded using an RF-5301
PC Hitachi spectroﬂuorometer Model F-2000 (Hitachi, Tokyo, Ja-
pan) equipped with a 150 W Xenon lamp and a slit width of 5 nm.rights reserved. This is an open access article under the CC BY-NC-ND license
Fig. 1. Fluorescence spectra of BSA (5 μM) in the presence of FOS: 0 (a) to 45 μM
(j) at 298 K.
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for measurements. The absorption spectra were recorded on a
double beam CARY 50-BIO UV–vis spectrophotometer (Varian,
Australia) equipped with a 150 W Xenon lamp and a slit width of
5 nm. A 1.00 cm quartz cell was used for measurements. The pH of
solution was measured with an Elico LI120 pH meter (Elico Ltd.,
India). Circular dichroism measurements were recorded on a Jasco
J-715 spectropolarimeter (Tokyo, Japan) with a 0.2 cm quartz cell.
2.3. Methods
2.3.1. Fluorescence quenching study
Based on preliminary investigations, the concentration of BSA
was kept constant at 5 μM [6], while that of the drug was varied
from 5 to 45 μM. Fluorescence spectra were recorded at three
temperatures in the range of 300–500 nm upon excitation at
296 nm.
2.3.2. UV measurements
The UV–vis spectra were obtained by scanning the solution on
the spectrophotometer in the wavelength range of 240–320 nm.
BSA concentration was ﬁxed at 5 μM, while that of FOS was varied
from 5 to 45 μM in the presence of phosphate buffer.
2.3.3. SFS
SFS were obtained by scanning the excitation and emission
monochromator simultaneously. The spectrum behavior of tyr-
osine and tryptophan residues of BSA was observed (Δλ¼15 nm
and Δλ¼60 nm). The spectra were recorded in the range of 250–
320 nm.
2.3.4. 3D ﬂuorescence spectra
The three-dimensional ﬂuorescence spectra of BSA were re-
corded. 40 mL (5 mM) of protein solution was transferred to a
quartz cell, diluted to 2.0 mL with phosphate buffer and mixed
well. To this, 360 mL of 45 mM FOS was added and the 3D ﬂuor-
escence spectra were recorded by scanning excitation wavelength
in the range of 200–350 nm and emission wavelength from 200 to
600 nm at an interval of 10 nm. The scanning parameters were just
the same as the ﬂuorescence quenching experiments.
2.3.5. Competitive binding studies
The competitive binding studies were performed by using dif-
ferent competitors, viz., warfarin for site I, ibuprofen for site II and
digitoxin for site III, by keeping the concentration of protein and
the competitor constant (each of 5 μM). The ﬂuorescence
quenching titration was performed as before, to determine the
binding constant of FOS–BSA in the presence of the above-said site
probes.
2.3.6. Effect of common ions
The ﬂuorescence spectra of FOS–BSA were recorded in the
presence of various common ions, viz., Ca2þ , Cu2þ , Mg2þ , Zn2þ
and Ni2þ , in the range of 300–500 nm upon excitation at 296 nm.
The overall concentration of BSA and that of the common ions
were ﬁxed at 5 μM.
2.3.7. Circular dichroism
The CD measurements of protein (2.5 μM) in the presence and
absence of FOS were made in the range of 200–260 nm. The ratio
of BSA to drug concentration was varied (1:0, 1:1 and 1:3) and the
CD spectra were recorded.
2.3.8. Molecular modeling
Molecular docking was performed with Surﬂex-Dock program
that is interfaced with Sybyl-X 2.0. [7]. Crystal structure of BSAwascomposed from PDB under code 3V03 [8] and was extracted from
the Brookhaven Protein Database (PDB http://www.rcsb.org/pdb).
All the hydrogen atoms were added to deﬁne the correct conﬁg-
uration and tautomeric states. Then the modeled structure was
energy-minimized using Tripos force ﬁeld with distance depen-
dent dielectric function and partial atomic charges were calculated
by AMBER7F9902 method and ﬁnally water molecules were re-
moved from the model. The geometry of the molecule FOS was
subsequently optimized to minimal energy using the Powell en-
ergy minimization algorithm, Tripos force ﬁeld with Gasteiger-
Hückel charges. FOS was then separately docked into the binding
pocket for docking–scoring analysis. To identify the ligand–protein
interactions, the top pose and protein were loaded into work area
and the Molecular Computer Aided Design (MOLCAD) program
was employed to visualize the binding mode between the protein
and ligand.3. Results and discussion
3.1. Fluorescence studies of BSA quenched by FOS
Fluorescence quenching refers to any process which decreases
the ﬂuorescence intensity of a sample [9]. The ﬂuorescence
emission spectra of BSA with increasing concentrations of FOS are
shown in Fig. 1. We measured the competitive absorbance of
protein and drug molecules at the excitation wavelength (296 nm)
and observed that both of them did not contribute to the inner
ﬁlter effect as evident from their very low absorbance values.
Hence, there was no inner ﬁlter effect. The possible mechanisms of
quenching include dynamic quenching, static quenching or both
[9,10]; dynamic and static quenching could be distinguished based
on their differing dependence on temperature. For this, we carried
out the quenching studies at different temperatures. For ﬂuores-
cence quenching, the decrease in intensity is usually described by
the SternVolmer equation [11] as shown below:
F
F
K Q K Q1 1
0
SV q 0τ= + [ ] = [ ] ( )
where F0 and F denote the steady-state ﬂuorescence intensities in
the absence and presence of quencher (FOS), respectively, KSV is
the SternVolmer quenching constant, and [Q] is the concentra-
tion of the quencher. Hence, Eq. (1) was applied to determine KSV
by linear regression of a plot F0/F against [Q] (Supplementary Fig.
S2). The values of KSV at different temperatures are given in
Table 1.
These values were found to decrease with increase of tem-
perature. This result conﬁrmed that the quenching is mainly a
Table 1
Stern–Volmer quenching constant KSV and Kq values.
System Temp (T) KSV (104) (L/mol) Kq (1012) (L/mol s)
BSA–FOS 288 1.6570.10 1.6570.10
298 1.1970.06 1.1970.06
308 1.0370.05 1.0370.05
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molecule, τ0 is the average lifetime of bio-molecule without the
quencher, and [Q] is the concentration of the quencher. Obviously,
K K / 2SV q 0τ= ( )
Since the lifetime ﬂuorescence of the biopolymer is 108 s [11],
the values of Kq for FOSBSA system were observed at different
temperatures as shown in Table 1. The order of magnitude of the
quenching rate constant Kq was observed to be 1012 in the present
study. However, the maximum scatter collision quenching con-
stant, Kq, of the various quenchers with the biopolymer [12] is
21010 (L/mol s). Thus, the rate constant calculated by protein
quenching procedure was greater than Kq of scatter procedure.
This indicated that a quenching mechanism was operative [13].
3.2. Binding parameters
3.2.1. Binding constant and binding sites
If it is assumed that there are similar and independent binding
sites in the biomolecule, for the static quenching interaction, the
binding constant (KA) and the number of sites (n) can be de-
termined according to the method described by Wei et al. [14],
using the equation:
⎛
⎝⎜
⎞
⎠⎟
F F
F
K n Qlog log log
3
0
A
− = + [ ]
( )
where KA is the binding constant of FOS with BSA and n is the
number of binding sites per albumin molecule, a plot of log(F0F)/
F versus log[Q] gives a straight line (Supplementary Fig. S3), whose
slopes equal n and the intercept on Y-axis equals log KA. The
corresponding values of KA and n at different temperature are
given in Table 2.
The values of n at the experimental temperatures were ap-
proximately equal to 1, which indicated that there was one class of
binding site to FOS with BSA. In BSA, the tryptophan residues in-
volved in binding can be either Trp134 or Trp212 of both trypto-
phans in BSA, and Trp134 is more exposed to a hydrophilic en-
vironment, whereas Trp212 is deeply buried in the hydrophobic
loop [13]. So, from the value of n, it was proposed that FOS most
likely binds to the hydrophobic pocket located in subdomain IIA.
That is to say, Trp212 is near or within the binding site [15].
3.2.2. Binding mode
The forces acting between drug and biomolecule may include
hydrogen bond, van der Waals force, electrostatic force and hy-
drophobic interaction force. The thermodynamic parameters, en-
thalpy change, entropy change and free energy change, are theTable 2
Thermodynamic parameters of FOS–BSA system.
System Temp. (K) Binding con-
stant (L/
mol103)
No. of
binding
sites (n)
ΔH0 (kJ/
mol)
ΔS0 (J/
K mol)
ΔG0 (kJ/
mol)
BSA–FOS 288 7.0570.35 0.916
298 4.7170.23 0.903 34.93 47.36 20.81
308 2.7370.14 0.901main evidences to determine the binding mode [16,17]. The
binding studies were carried out at different temperatures and
analyzed using the van’t Hoff equation [18] given below:
K
H
RT
S
R
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2.303 2.033 4A
0 0
= − Δ + Δ ( )
where KA is the binding constant at the corresponding tempera-
ture, and R is the gas constant and T is the temperature. The log KA
versus 1/T plot enabled the determination of ΔH0 (kJ/mol) and ΔS0
(J/K mol) values for the binding process. The value of ΔG0 was
calculated using the equation:
G H T S 50 0 0Δ = Δ − Δ ( )
and the corresponding values are presented in Table 2. ΔH0 and
ΔS0 for the interaction between FOS and BSA were found to be –
34.93 kJ/mol and –47.36 J/K mol, respectively. Thus, the negative
sign for ΔG0 meant that the binding process was spontaneous and
the formation of complex was an exothermic reaction accompa-
nied by negative ΔS0 value. Besides, the negative ΔH0 and ΔS0
values revealed that the interaction forces between FOS and BSA
were owing to van der Waals force and hydrogen bonds. However,
electrostatic interactions might play a role in the interaction [17].
3.2.3. Binding distance
Fluorescence resonance energy transfer (FRET) [19] occurs
whenever the emission spectrum of the ﬂuorophore (donor)
overlaps with the absorption spectrum of the acceptor. Basically,
efﬁciency of the FRET mainly depends on the following three
parameters: (i) the distance between donor and acceptor (which
must be within the speciﬁed Förster distance of 2–8 nm); (ii) ap-
preciable overlap between the donor ﬂuorescence and acceptor
absorption band; and (iii) proper orientation of the transition di-
pole of the donor and acceptor. The distance between the donor
and acceptor could be calculated according to Förster’s theory [20].
The efﬁciency of energy transfer, E, was calculated using
E
F
F
R
R r
1
60
0
6
0
6 6
= − =
+ ( )
where F and F0 are the ﬂuorescence intensities of donor in the
presence and absence of the acceptor, respectively. r represents
the acceptor–donor distance and R0 is the critical distance when
the transfer efﬁciency is 50%. R0 can be expressed as
R k N J8.8 10 70
6 25 2 4Φ= × ( )− −
where k2 is the spatial orientation factor of the dipole, N is the
refractive index of the medium, Φ is the ﬂuorescence quantum
yield of the donor and J is the overlap integral of the ﬂuorescence
emission spectrum of the donor and the absorption spectrum of
the acceptor [21]. J is given by
J
F
F 8
4λ ε λ λ λ
λ λ
= ∑ ( ) ( ) Δ∑ ( )Δ ( )
where F(λ) is the ﬂuorescence intensity of the ﬂuorescent donor at
wavelength λ and ε(λ) is the molar absorption coefﬁcient of the
acceptor at wavelength λ. In the present case, k2¼2/3, n¼1.36 and
Ф¼0.15 [22]. From Eqs. (6)–(8), J¼1.8651014 (cm3 L/mol),
R0¼2.831 nm, E¼0.074 and r¼4.99 nm for FOS–BSA system can
be calculated. The value of r indicates that the donor and acceptor
are close to each other and hence they have strong binding
between them [23]. Furthermore, the observed donor-to-acceptor
distance ro8 nm revealed the presence of static quenching in the
interaction [24].
Table 3
Effect of common ions on binding constant of FOS–BSA.
Systems (cations) Binding constant (M103)
BSAþFOS 4.714
BSAþFOSþCa2þ 3.526
BSAþFOSþCu2þ 3.068
BSAþFOSþMg2þ 2.288
BSAþFOSþNi2þ 1.806
BSAþFOSþZn2þ 1.530
Fig. 2. Synchronous ﬂuorescence spectrum of BSA–FOS (T¼298 K, pH 7.40): (A)
Δλ¼15 nm and (B) Δλ¼60 nm. (a) [BSA]¼5 μM; (b)–(j) [FOS]¼5–45 μM.
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Some common ions are widely distributed in humans and an-
imals, which can affect the interactions of compounds with serum
albumin. Therefore, we examined the effects of some cations
(Ca2þ , Cu2þ , Mg2þ , Ni2þ and Zn2þ) on binding of FOS with pro-
tein at 298 K. The binding constant values (Table 3) of FOS–protein
were noticed to decrease in the presence of the above metal ions.
This indicated that the drug would be quickly cleared from the
blood [25]. In such an event, it necessitated to readjust the dose
limits of the drug in the presence of these metal ions.
3.2.5. Binding studies using UV–visible absorption spectra
UV–vis absorption measurement is a very simple method and
applicable to explore the structural change and know the complex
formation [26]. The UV–vis absorption spectra of FOS, BSA and the
FOS–BSA system were also investigated to conﬁrm the probable
quenching mechanism. The UV–vis absorbance intensity de-
creased regularly with the increasing concentration of FOS [27],
indicating that the BSA molecules were associated with FOS and
formed a FOS–BSA complex. This conﬁrmed again a static
quenching mechanism.
3.2.6. Site probe studies
Sudlow et al. [28] suggested two main distinct binding sites
(sites I and II) in BSA. Site I of BSA has afﬁnity for warfarin and site
II for ibuprofen. It was reported that the binding of digitoxin is
independent of sites I and II [29] and binds to site III. In order to
establish the binding site in the BSA for FOS, competitive binding
studies were performed using site probes, warfarin, ibuprofen and
digitoxin, in connection with Sudlow’s classiﬁcation of the binding
sites. Table 4 shows the binding constant of FOS–BSA in presence
of different site markers. As evident from Table 4, FOS was not
signiﬁcantly displaced by ibuprofen or digitoxin. However, war-
farin (site I) showed a displacement of FOS, suggesting that FOS
bound to site I of BSA, which is located in the hydrophobic pocket
of subdomain II A [6].
3.3. Conﬁrmation investigation
3.3.1. Synchronous ﬂuorescence study
To explore the structural change of BSA by the addition of FOS,
SFS (Fig. 2) of BSA were measured with various amounts of FOS.
The SFS give information about the molecular environment in a
vicinity of the chromosphere molecules and have severalTable 4
The comparison of binding constants of FOS–BSA before and after the addition of
site probe.
Systems Binding constant (M)
BSAþFOS 4.714103
BSAþFOSþWarfarin 1.397102
BSAþFOSþ Ibuprofen 4.694103
BSAþFOSþDigitoxin 4.348103advantages, such as sensitivity, spectral simpliﬁcation, spectral
bandwidth reduction as well as avoiding different perturbing ef-
fects [30]. Yuan et al. [31] suggested a useful method to study the
environment of amino acid residues by measuring the possible
shift in wavelength emission maximum λmax, the shift in position
of emission maximum corresponding to the changes of the po-
larity around the chromophore molecule. When the D-value (Δλ)
between excitation wavelength and emission wavelength was
stabilized at 15 or 60 nm, the SFS gave the characteristic in-
formation of tyrosine residues or tryptophan residues, respec-
tively. The effect of FOS on protein SFS is shown in Fig. 2(A) and
(B).
In Fig. 2(A), it is observed that there is a gradual decrease of the
ﬂuorescence intensity of tyrosine residues and a blue shift at the
maximum emission upon addition of FOS, which indicated that
the binding between FOS and the protein is located in close
proximity to the tyrosine residues. The conformation of BSA was
changed, and it suggested a less polar (or more hydrophobic) en-
vironment of tyrosine residue [32]. While in Fig. 2(B), the max-
imum emission wavelength of tryptophan residues showed a blue
shift, which indicates that the conformation of BSA was changed
such that the polarity around the tryptophan residues decreased
and the hydrophobicity was increased [33].
3.3.2. 3D ﬂuorescence
It is well known that 3D ﬂuorescence spectra can provide more
detailed information about the conformational changes of pro-
teins. The maximum emission wavelength and the ﬂuorescence
intensity of the residues have a close relation to the polarity of
their micro-environment [34,31]. By comparing the 3D ﬂuores-
cence spectral changes of BSA in the absence and presence of FOS,
we can investigate the conformational and micro-environmental
changes of BSA. The 3D ﬂuorescence spectra of BSA and the
Fig. 3. Three dimensional ﬂuorescence spectra of (A) BSA and (B) the FOSþBSA system.
Table 5
Three-dimensional ﬂuorescence spectral characteristics of HSA and the HSA–FOS
system.
System Peak a Peak b
BSA Peak position (Ex/Em) 250/250–360/360 290/340
Relative intensity (F) 4.984–6617 5106
BSA–FOS Peak position (Ex/Em) 250/250–360/360 290/340
Relative intensity (F) 9.4–6933 3793
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mension ﬂuorescence spectra of BSA in the presence of different
volumes of FOS are listed in Table 5.
In addition, the contour map provides bird’s eye view of 3D
ﬂuorescence spectra. Peak ‘a’ denotes the Raleigh scattering peak
(λex¼λem), whereas strong peak ‘b’ mainly reveals the spectral
characteristics of Trp and Tyr residues on proteins, and another
peak ‘c’ is the second-order scattering peak (λem¼2λex).
In Fig. 3, the ﬂuorescence intensity of peak ‘a’ increased with the
addition of FOS. The possible reason was FOS–BSA complex forma-
tion after FOS was added. So the diameter of the macromolecule
increased and resulted in the enhanced scattering effect [35]. Peak ‘b’
mainly reﬂected the spectral behavior of Trp and Tyr residues. The
ﬂuorescence intensity of peak ‘b’ decreased markedly and the max-
imum emission wavelength of the peak was changed following the
addition of FOS. Peak ‘c’ was the second order scattering peak
(λem¼2λex), analyzing from the intensity changes of peak ‘a’ and peak
‘b’ revealed that the binding of FOS to BSA induced some con-
formational and micro-environmental changes in BSA [36].
3.3.3. Circular dichroism spectra
CD is a powerful tool in elucidating the modiﬁcations of the
secondary structure of biopolymers as a result of interaction with
small molecules. The far UVCD spectra of BSA exhibit a typical
shape of a α-helix-rich secondary structure (two minima atapproximately 208 and 222 nm). BSA has a high percentage of α-
helical structure, which shows characteristic strong double mini-
mum signals at 222 and 208 nm, which represents the transition
of ππ* and n–π* of α-helix structure [37]. The results of CD were
expressed in terms of the mean residue ellipticity (MRE) in ac-
cording to the following equation
C nl
MRE
observed CD mdeg
10 9P
= ( )
× ( )
where Cp is the molar concentration of the protein, n is the
number of amino acid residues and l is the path length. The α-
helical contents of free and combined BSA were calculated from
MRE values at 208 nm using the following equation [38]
helix %
MRE 4000
33, 000 4000
100
10
208[ ]α− ( ) = − −
[ − ]
× ( )
where MRE208 is the observed MRE value at 208 nm, 4000 is the
MRE of the β-form and random coil conformation cross at 208 nm
and 33,000 is the MRE value of a pure α-helix at 208 nm. The CD
spectra of BSA in the absence and presence of different con-
centrations of FOS are shown in Fig. 4.
From the above equation, the percentage of helicity of BSA is
from 62% in free BSA (Fig. 4) to 67% and 79% in the presence of
FOS–BSA, which showed that binding of FOS to BSA might induce
some conformational changes. However, the shape of peaks and
the peak maximum position remained almost the same. This in-
dicated that BSA has predominantly α-helix nature even after
binding to the drug. In the presence of FOS, no appreciable per-
turbation of secondary and tertiary structures in the protein is
observed (Fig. 4). Thus, FOS, the aromatic and peptide regions do
not show any appreciable change in the CD spectra.
3.3.4. Molecular modeling results
Surﬂex-docking was employed to understand the interaction
between BSA and FOS and to ultimately elucidate the interaction
Fig. 4. The CD spectra of the FOS–BSA system: (a) free BSA, (b) and (c) BSAþFOS
obtained at 298 K and at pH¼7.4.
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20 conformations of FOS. We selected the best conformation for
further analysis, owing to its higher binding afﬁnity (4.50 kcal/
mol) and the lowest molecular energy. Fig. 5(A) and (B) with best
conﬁrmation shows four H-bonds, oxygen at phosphate making
one H-bond with Trp213 (P¼O––HN–Trp213, 1.91 Å), that of
oxygen of OH making H-bond with Arg194 (HO––HN–Arg194,
2.11 Å), hydrogen of same OH making two H-bonds with Asp450
(OH––OC–Asp450, 2.02, 2.67 Å). FOS was surrounded with hy-
drophobic amino acids (Leu197, Ala200, Phe205, Trp213, Ala216,Fig. 5. (A) Details of the interactions between BSA and FOS in the docked model. (B)
(D) hydrophilic amino acids surrounded to FOS. (E) and (F) Binding domain for FOS atAla296, Pro338, Val342, Leu454, Val461, Leu480) and hydrophilic
amino acids (Arg194, Arg196, Ser201, Lys204, Glu293, Lys294, Asn457,
Glu464) (Fig. 5(C) and (D)). Fig. 5(E) and (F) represents the binding
domain for FOS at the active site of BSA chain A. The principal ligand
binding site on BSA is located in the hydrophobic cavities in sub-
domains IIA and IIIA, which are consistent with sites I and II. It is
important to note that Trp213 is in subdomain IIA, from the
H-bonding interactions and surrounded amino acids, which indicated
that the binding location was Sudlow’s site I in subdomain IIA.4. Conclusions
In this work, we used different approaches to explore the in-
teractions between FOS and BSA under physiological conditions.
The experimental results clearly showed that FOS quenches the
ﬂuorescence of BSA by a static quenching mechanism. This work
provided a more comprehensive study on the distance between
the donor (protein) and acceptor (FOS) based on ﬂuorescence re-
sonance energy transfer. Experimental results from the quantita-
tive analysis of circular dichroism, three dimensional ﬂuorescence
studies and synchronous ﬂuorescence spectrum demonstrated
that the binding of FOS to BSA induced some micro-environmental
and conformational change of serum albumin. Our study is ex-
pected to provide important insights into the interactions of the
physiologically important protein with FOS, facilitating further
investigation on the pharmacological behavior of FOS. This type of2D schematic representation of hydrogen bond interactions. (C) Hydrophobic and
BSA chain A.
M.D. Meti et al. / Journal of Pharmaceutical Analysis 5 (2015) 249–255 255investigation on drug–protein interaction assumes importance in
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